Key takeaways
Saphnelo (anifrolumab-fnia) and Benlysta (belimumab) are both biologic medications that treat systemic lupus erythematosus (SLE). However, they differ in several ways. Saphnelo is administered as an intravenous (IV) infusion once a month. Benlysta comes as both an IV infusion given every 2 to 4 weeks or an under-the-skin injection you can give yourself at home once weekly. Benlysta is also FDA-pproved for treating lupus nephritis, while Saphnelo is not. Both medications are brand-name only and can be costly, but savings programs are available. Common side effects of Saphnelo include upper respiratory infections and infusion-related reactions. Benlysta side effects include nausea, diarrhea, and infusion or injection-related reactions. Both medications increase the risk of serious infections, and you should avoid live vaccines while receiving them.
